Insider Selling: PRA Health Sciences, Inc. (PRAH) CEO Sells 400,000 Shares of Stock

PRA Health Sciences, Inc. (NASDAQ:PRAH) CEO Colin Shannon sold 400,000 shares of PRA Health Sciences stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

PRA Health Sciences, Inc. (NASDAQ PRAH) opened at 74.76 on Friday. The stock has a 50 day moving average price of $75.23 and a 200-day moving average price of $67.94. The stock has a market cap of $4.68 billion, a PE ratio of 48.26 and a beta of 0.45. PRA Health Sciences, Inc. has a 1-year low of $48.42 and a 1-year high of $80.99.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.72 by $0.10. The firm had revenue of $457.90 million during the quarter, compared to analysts’ expectations of $447.79 million. PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $0.63 EPS. On average, equities analysts expect that PRA Health Sciences, Inc. will post $3.19 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/insider-selling-pra-health-sciences-inc-prah-ceo-sells-400000-shares-of-stock.html.

A number of equities research analysts have recently weighed in on the company. Raymond James Financial, Inc. assumed coverage on PRA Health Sciences in a research report on Wednesday. They issued an “outperform” rating and a $89.00 price objective on the stock. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a research report on Tuesday. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 price objective (up from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Citigroup Inc. reiterated a “buy” rating and issued a $93.00 price objective (up from $90.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating on shares of PRA Health Sciences in a research report on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. PRA Health Sciences currently has a consensus rating of “Buy” and an average price target of $81.22.

A number of institutional investors have recently modified their holdings of PRAH. Dynamic Technology Lab Private Ltd purchased a new position in shares of PRA Health Sciences during the second quarter worth about $359,000. Ameritas Investment Partners Inc. raised its position in shares of PRA Health Sciences by 62.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,404 shares of the medical research company’s stock worth $255,000 after buying an additional 1,315 shares during the period. California State Teachers Retirement System raised its position in shares of PRA Health Sciences by 44.1% in the second quarter. California State Teachers Retirement System now owns 68,668 shares of the medical research company’s stock worth $5,151,000 after buying an additional 21,031 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of PRA Health Sciences by 56.7% in the second quarter. The Manufacturers Life Insurance Company now owns 30,553 shares of the medical research company’s stock worth $2,292,000 after buying an additional 11,057 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of PRA Health Sciences by 160.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 99,600 shares of the medical research company’s stock worth $7,471,000 after buying an additional 61,400 shares during the period. Institutional investors own 96.76% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Insider Buying and Selling by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply